T cell epitope mapping of secukinumab and ixekizumab in healthy donors

• Hauptverfasser: Sebastian Spindeldreher (Verfasst von), Anette Karle (Verfasst von), Evelyne Correia (Verfasst von), Maxime Tenon (Verfasst von), Sascha Gottlieb (Verfasst von), Thomas Huber (Verfasst von), Bernard Maillere (Verfasst von), Frank Kolbinger (Verfasst von)
• Format: Buch
• Veröffentlicht: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has consistently shown low anti-drug antibody responses in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab has also shown lower in vitro immunogenicity potential compared with other mo...